Investor

Curasight’s mission is to build leadership in precision oncology by developing a uPAR-based radioligand therapy platform for aggressive solid tumors with unmatched precision and individualization across multiple indications.

Curasight is a clinical-stage radiopharmaceutical company headquartered in Copenhagen and listed on the Spotlight Stock Market in Sweden.